Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
11.16 USD +2.39% Intraday chart for LifeMD, Inc. +13.07% +34.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating MT
LifeMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : LifeMD, Inc., Q4 2023 Earnings Call, Mar 11, 2024
Earnings Flash (LFMD) LIFEMD Reports Q4 Revenue $44.9M, vs. Street Est of $40.5M MT
Earnings Flash (LFMD) LIFEMD Posts Q4 EPS $0.15, vs. Street Est of $0.03 MT
LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024 CI
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating MT
LifeMD Provides 2024 Financial Guidance RE
LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
WeightWatchers Stock Drops 12% After Eli Lilly Launches DTC Weight-Loss Drug Service DJ
Medifast, LifeMD Collaborate to Offer Weight Management Solution; Medifast Scraps Quarterly Dividend MT
Transcript : LifeMD, Inc., Medifast, Inc. - Special Call
Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, Inc CI
LifeMD, Inc. announced that it has received $10.000001 million in funding from Jason Pharmaceuticals, Inc. CI
LifeMD, Inc. announced that it expects to receive $10.000001 million in funding from Jason Pharmaceuticals, Inc. CI
Lifemd, Inc. Announces Resignation of Bertrand Velge from His Position as Member of the Board of Directors CI
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating MT
LifeMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : LifeMD, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (LFMD) LIFEMD Posts Q3 Revenue $38.6M, vs. Street Est of $38.2M MT
Chart LifeMD, Inc.
More charts
LifeMD, Inc. is a direct-to-patient telehealth company, which provides comprehensive virtual and in-home healthcare. The Company operates through two segments: Telehealth and WorkSimpli. Telehealth segment is engaged in telehealth platform, which integrates a clinician-centric electronic medical record (EMR) system, algorithms for case-load balancing and scheduling, customer relationship management functionality, asynchronous communication, secure synchronous, cloud pharmacy and more. Its technology platform, combined with its 50-state affiliated provider network, enables the management of virtual treatment offerings across various health conditions, including, dermatology, urgent and primary care, chronic care management, dermatology, chronic care management and other. Its WorkSimpli segment offers workplace and document services. This segment offers PDFSimpli an online software as a service platform that allows users to create, edit, convert, sign and share PDF documents.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.16 USD
Average target price
12.8 USD
Spread / Average Target
+14.70%
Consensus
  1. Stock Market
  2. Equities
  3. LFMD Stock
  4. News LifeMD, Inc.
  5. Conversion Labs : BTIG Starts Conversion Labs at Buy With $15 Price Target